Nutritional modulators of neuropsychiatric dysfunction

Open Nutraceuticals Journal

Volumn 4, Issue , 2011, Pages 52-60

  Wilczynska, Agnieszka ^a,b   Singh, Ram B ^c   de Meester, Fabien ^b,d  

^a UNIVERSITY OF SILESIA   (Poland)

^b TsimTsoum Institute Krakow   (Poland)

^c HALBERG HOSPITAL AND RESEARCH INSTITUTE   (India)

^d Columbus Paradigm Institute ^*  (Belgium)

Author keywords

Anxiety; Depression; Diets; Food; Nutraceuticals; Nutrients; Type A behaviour

Indexed keywords

ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; LINOLENIC ACID; LIPID; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; POLYUNSATURATED FATTY ACID;

DEMENTIA; DEPRESSION; DIET SUPPLEMENTATION; DIETARY INTAKE; FATTY ACID ANALYSIS; HUMAN; LIPID BLOOD LEVEL; MENTAL DETERIORATION; MENTAL FUNCTION; MENTAL HEALTH; NEUROLOGIC DISEASE; NEUROPROTECTION; NEUROPSYCHIATRY; NUTRIENT SUPPLY; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA;

EID: 79959973564     PISSN: None     EISSN: 18763960     Source Type: Journal    
DOI: 10.2174/1876396001104010052     Document Type: Review

References (96)

1. Salem N Jr, Litman B, Kim HY, Gawrish K. Mechanisms of action of docosahexaenoic acid in the nervous system. Lipids 2001; 36: 945-59.
2. Piomelli D. Eicosanoids in synaptic transmission. Crit Rev Neurbiol 1994; 8: 65-83.
3. Haag M. Essential fatty acids and the brain. Can J Psychiatr 2003; 48: 195-203
4. Jones CR, Arrai T, Rapoport SI. Evidence for the involvement docosahexanoic acid in chollinergic stimulated signal transduction at the synapse. Neurochem Res 1997; 22: 663-70.
5. Singh R. Study of Nutrition, Anxiety, Stress and Behaviour in Relation to Cardiovascular Risk Factors in the Elderly Urban Population of Moradabad, India, Thesis for PhD, Department of Psychology, Gokuldas Girls College, Moradabad, Rohilkhand University, Bareilly, 1998.
6. Singh RB, Niaz MA, Ghosh S, et al. Dietary intake, and plasma levels of antioxidant vitamins in health and disease, case study. J Nutr Environ Med 1995; 5: 235-42.
7. Anderson GH. Diet, neurotransmitters and brain function. Br Med Bull 1981; 37: 95-100.
8. Wurtman RJ. Behavioural effects of nutrients. Lancet 1983; 1: 1145-7.
9. Maes M, Mihaylova I, Kubera M, Bosmans E. Why fish oils may not always be adequate treatments for depression or other inflammatory illnesses: docosahexaenoic acid, an omega-3 polyunsaturated fatty acid, induces a Th-1-like immune response. Neuro Endocrinol Lett 2007; 28: 875-80.
10. Colin A, Reggers J, Castronovo V, Ansseau M. Lipids, depression and suicide. Encephale 2003; 29(1): 49-58.
11. Su KP. Mind-body interface: the role of n-3 fatty acids in psychoneuroimmunology, somatic presentation, and medical illness comorbidity of depression. Asia Pac J Clin Nutr 2008; 17(Suppl 1): 151-7.
12. Sontrop J, Campbell MK. Omega-3 polyunsaturated fatty acids and depression: a review of the evidence and a methodological critique. Prev Med 2006; 42(1): 4-13.
13. Lin PY, Su KP. A meta-analytic review of double-blind, placebo-controlled trials of antidepressant efficacy of omega-3 fatty acids. J Clin Psychiatry 2007; 68(7): 1056-61.
14. Kronenberg G, Harms C, Sobol RW, et al. Folate deficiency induces neurodegeneration and brain dysfunction in mice lacking uracil DNA glycosylase. J Neurosci 2008; 28(28): 7219-30.
15. Joseph JA, Shukitt-Hale B, Lau FC. Fruit polyphenols and their effects on neuronal signaling and behavior in senescence. Ann NY Acad Sci 2007; 1100: 470-85.
16. Delion S, Cahlon S, Guilloteau G, et al. Chronic dietary alphalinolenic acid deficiency alters dopaminergic and serotinergic neurotransmission in rats. J Nutr 1994; 124: 266-76.
17. Delion S, Cahlon S, Guilloteau G, et al. Alpha-linolenic acid deficiency alters age-related changes of dopaminergic and serotoninergic neurotransmission in the rat frontal cortex. J Neurochem 1996; 66: 1582-91.
18. Hibbeln JR, Salem N. Dietary polyunsaturated fatty acids and depression: when cholesterol does not satisfy. Am J Clin Nutr 1995; 62: 1-9.
19. Yehuda S, Rabinovitz S. Crasso RL, Mostofsky DI. The role of polyunsaturated fatty acids in restoring the aging of neuronal membrane. Neurobiol Ageing 2002; 23: 843-53.
20. Martin RE, Bazan NG. Changing fatty acid content of growth cone lipids prior to synaptogenesis. J Neurochem 1992; 59: 318-25.
21. Neuringer M, Reisbick S, Janowsky J. The role of omega-3 fatty acids in visual and cognitive development: Current evidence and methods of assessments. J Pediatr 1994; 125: S39-47.
22. Willats P. Long chain polyunsaturated fatty acids improve cognitive development. J Fam Health Care 2002; 12 (S6): 5.
23. Bakker EC, Ghys AJ, Kester AD, et al. Long-chain polyunsaturated fatty acids at birth and cognitive function ant 7 y of age. Eur J Clin Nutr 2003; 57: 89-95.
24. Helland IB, Smith L, Saarem K, Saugstad OD, Drevon CA. Maternal supplementation with very-long-chain Omega-3 fatty acids during pregnancy and lactation augments children's IQ at four years of age. Pediatrics 2003; 111: 39-44.
25. McCann JC, Ames BN. Is docosahexaenoic acid, an n-3 long-chain polyunsaturated fatty acid, required for development of normal brain function? An overview of evidence from cognitive and behavioral tests in humans and animals. Am J Clin Nutr 2005; 82(2): 281-95.
26. Yehuda S, Rabinovitz S, Mostofsky DI. Essential fatty acids are mediators of brain biochemistry and cognitive functions. J Neurosci Res 1999; 56: 565-70.
27. Yehuda S. Omega-6/Omega-3 ratio and brain related functions. World Rev Nutr Diet 2003; 92: 37-56.
28. La Guardia M, Giammanco S, Di Majo D, Tabacchi G, Tripoli E, Giammanco M. Omega 3 fatty acids: biological activity and effects on human health. Panminerva Med 2005; 47(4): 245-57.
29. Innis SM. Dietary (n-3) fatty acids and brain development. J Nutr 2007; 137: 855-9.
30. Mazza M, Pomponi M, Janiri L, Bria P, Mazza S. Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: An overview. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 12-26.
31. Fabrigoule C, Rouch I, Taberly A, et al. Cognitive procces in preclinical phase of dementia. Brain 1998; 121: 135-41.
32. Freeman MP. Omega-3 fatty acids in psychiatry: a review. Ann Clin Psychiatry 2000; 12: 159-65.
33. Hakkarainen R, Partonen T, Haukka J, Albanes D, Lonnqvist J. Is low dietary intake of omega-3 fatty acid associated with depression? Am J Psychiatry 2004; 161: 567-9.
34. Stoll AL, SeverusWE, Freeman MP, et al. Omega-3 fatty acids in bipolar disorder - a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 1999; 56: 407-12.
35. Hibbeln JR. Fish consumption and major depression. Lancet 1998; 351: 1213.
36. Silvers KM, Scott KM. Fish consumption and self physical and mental health status. Public Health Nutr 2002; 5: 427-31.
37. Timonen M, Horrobin DF, Jokelainen J, Laitinen JM, Herva AM, Rasanen P. Fish consumption and depression: the Northern Finland 1966 birth cohort study. J Affect Disord 2004; 82: 447-52.
38. Noaghiul S, Hibbeln JR. Cross-national comparisons of seafood consumption and rates of bipolar disorders. Am J Psychiatry 2003; 160: 2222-7.
39. Cott J, Hibbeln JR. Lack of seasonal mood change in Icelanders. Am J Psychiatry 2001; 158: 328.
40. Parker G, Gibson NA, Brotchie H, Heruc G, Rees A, Hadzi-Pavlovic D. Omega-3 fatty acids and mood disorders. Am J Psychitry 2006; 163: 969-78.
41. Klerman GL, Weissman MM. Increasing rates of depression. JAMA 1989; 261: 2229-35.
42. Edwards R, Peet M, Shay J, Horrobin D. Depletion of docosahexaenoic acid in red blood cell membranes of depressive patients. Biochem Soc Trans 1998; 26: S142.
43. Peet M, Murphy B, Shay J, Horrobin D. Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychol 1998; 43: 315-9.
44. Tiemeier H, van Tuijl HR, Hoffman A, Kiliaan AJ, Breteler MM. Plasma fatty acid composition and depression are associated in the elderly: the Rotterdam study. Am J Clin Nutr 2003; 78(1): 40-6.
45. Nemets B, Stahl Z, Belmaker RH. Addition of omega-3 fatty acid to maintenance medication treatment for recurrent unipolar depressive disorder. Am J Psychiatry 2002; 159: 477-9.
46. Tanskanen A, Hibbeln JR, Tuomilehto J. Fish consumption and depressive symptoms in general population in Finland. Psychiatr Serv 2001; 52: 529-31.
47. Tanskanen A, Hibbeln JR, Hintikka J. Fish consumption, depression, and suicidality in a general population. Arch Gen Psychiatry 2003; 58: 512-3.
48. Huan M, Hamazaki K, Sun Y, et al Suicide attempt and n-3 fatty acid levels in red blood cells: a case control study in China. Biol Psychiatry 2004; 56: 490-6.
49. Fontani G, Corradeshi F, Felici A, Alfatti F, Migliorini S, Lodi L. Cognitive and physiological effects of Omega-3 polyunsaturated fatty acid supplementation in healthy subjects. Eur J Clin Invest 2005; 35(11): 691-9.
50. Hamazaki T, Sawazaki S, Itomura M. The effect of docosahexaenoic acid on aggression in young adults. A placebo-controlled double-blind study. J Clin Invest 1996; 97: 1129-33.
51. Werneke U, Turner T, Priebe S. Complementary medicines in psychiatry: review of effectiveness and safety. Br J Psychiatry 2006; 188: 109-201.
52. Appleton KM, Hayward RC, Gunnell D, Peters TJ, Rogers PJ, Kessler D, Ness AR. Effects of n-3 long-chain polyunsaturated fatty acids on depressed mood: systematic review of published trials. Am J Clin Nutr 2007; 85(6): 1665-6.
53. Appleton KM, Gunnell D, Peters TJ, Ness AR, Kessler D, Rogers PJ. No clear evidence of an association between plasma concentrations of n-3 long-chain polyunsaturated fatty acids and depressed mood in a non-clinical population. Prostaglandins Leukot Essent Fatty Acids 2008; 78(6): 337-42.
54. Silvers KM, Woolley CC, Hamilton FC, Watts PM, Watson RA. Randomised double-blind placebo-controlled trial of fish oil in the treatment of depression. Prostaglandins Leukot Essent Fatty Acids 2005; 72: 211-8.
55. Hakkarainen R, Partonen T, Haukka J, Virtamo J, Albanes D, Lonnqvist J. Is low dietary intake of omega-3 fatty acids associated with depression? Am J Psychiatry 2004; 161: 567-9.
56. Rogers PJ, Appleton KM, Kessler D, et al. No effect of n-3 long-chain polyunsaturated fatty acid (EPA and DHA) supplementation on depressed mood and cognitive function: a randomised controlled trial. Br J Nutr 2008; 99:421-431.
57. Behan PO, Behan WMH, Horrobin D. Effect of high doses of essential fatty acids on the postviral fatigue syndrome. Acta Neurol Scand 1990; 82: 209-16.
58. Warren G, McKendrick M, Peet M. The role of essential fatty acids in chronic fatigue syndrome. Acta Neurol Scand 1999; 99: 112-6.
59. Fenton WS, Dickerson F, Boronow J, Hibbeln JR, Knable M. A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia. Am J Psychiatry 2001; 158: 2071-4.
60. Peet M, Brind J, Ramchand CN, et al. Two double-blind placebo-controlled pilot studies of eicosapenaenoic acid in the treatment of schizophrenia. Schizophr Res 2001; 49: 243-51.
61. Voigt G, Llorente AM, Jensen CL, Fraley JK, Barretta MC, Heird WC. A randomized double-blind, placebo-controlled trial of docosahexaenoic acid supplementation in children with attention-deficit/hyperactivity disorder. J Pediatr 2001; 139: 189-96.
62. Keck PE, Freeman MP, McElroy SL, et al. A double-blind placebo controlled trial of eicosapentaenoic acid in rapid cycling bipolar disorder. Bipolar Disord 2002; 4(suppl): 26-7.
63. Peet MB, Horrobin DF. A dose-ranging study of the effects of ethyleicosapentaenoate in patients with ongoing depression despite apparently adequate treatment with standard drugs. Arch Gen Psychiatry 2003; 59: 913-9.
64. Emsley R, Myburgh C, Oosthuizen P, van Rensburg SJ. Randomized, placebo-controlled study of ethyleicosapentaenoic acid as supplemental treatment in schizophrenia. Am J Psychitry 2002; 159; 1596-8.
65. Peet M, Horrobin DF, E-E Multicentre Study Group. A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms. J Psychiatr Res 2002; 36; 7-18.
66. Richardson AJ, Puri BK. A randomised double-blind, placebo-controlled study of the effects of supplementation with highly unsaturated fatty acids on ADHD-related symptoms in children with specific learning difficulties. Prog Neuropsychpharm Biol Psychiatry 2002; 26: 233-9.
67. Llorente AM, Jensen CL, Voigt RG, et al. Effect of maternal docosahexaenoic acid supplementation on postpartum depression and information processing. Am J Obstet Gynecol 2003; 188: 1348-53.
68. Marangell LB, Martinez JM, Zboyan HA, Kertz B, Seung Kim HF, Puryear LJ. A double-blind, placebo-controlled study of the omega-3 fatty acid docosahexaenoic acid in the treatment of major depression. Am J Psychiatry 2003; 160: 996-8.
69. Su KP, Huang SY, Chiu CC, Shen WW. Omega-3 fatty acids in major depressive disorder - a preliminary double-blind placebo-controlled trial. Eu Neuropsychopharmacol 2003; 13: 267-71.
70. Zanarini MC, Frankenburg MD. Omega-3 fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry 2003; 160: 167-9.
71. Post RM, Leverich GS, Altshuler LL, et al. An overview of recent findings of the Stanley foundation bipolar network (part I). Bipolar Disord 2003; 5: 310-9.
72. Fux M, Benjamin J, Nemets B. A placebo-controlled cross-over trial of adjunctive EPA in OCD. J Psychosom Res 2004; 38: 323-5.
73. Hirashima F, Parow AM, Stoll AL, et al. Omega-3 fatty acid treatment and T2 whole brain relaxation times in bipolar disorder. Am J Psychiatry 2004; 161: 1922-4.
74. Hirayama S, Hamazaki T, Terasawa K. Effect of docohexaenoic acid-containing food administration on symptoms of attention-deficit/hyperactivity disorder - a placebo-controlled double-blind study. Eur J Clin Nutr 2004; 58: 467-73.
75. Fontani G, Corradeshi F, Felici A, et al. Blood profiles, body fat and mood state in healthy subjects on different diets suplemented with omega-3 polyunsaturated fatty acids. Eur J Clin Invest 2005; 35: 499-507.
76. Osher Y, Bersudsky Y, Belmaker RH. Omega-3 Eicosapentaenoic Acid in Bipolar Depression: Report of Smal Open Label Study. J Clin Psychiatry 2005; 66: 726-9.
77. Freeman MP, Hibbeln JR, Wisner KL, Brumbach BH, Watchman M, Gelenberg AJ. Randomized dose-ranging pilot trial of omega-3 fatty acids for postpartum depression. Acta Psychiatr Scand 2006; 113: 31-5.
78. Frangou S, Lewis M, McCrone P. Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry 2006; 188: 46-50.
79. Nemets H, Nemets B, Apter A, Bracha Z, Belmaker RH. Omega-3 treatment of children's depression: a controlled, double-blind pilot study. Am J Psychiatry 2006; 163: 1098-100.
80. Hallahan B, Hibbeln JR, Davis JM, Garland MR. Omega-3 fatty acid supplementation in patients with recurrent self-harm: Single -centre double-blind randomised controlled trial. Br J Psychiatry 2007; 190: 118-22.
81. Amminger GP, Berger GE, Schafer MR, Klier C, Friedreich MH, Feucht M. Omega-3 fatty acids supplementation in children with autism: a double-blind randomized, placebo-controlled pilot study. Biol Psychiatry 2007; 61: 551-3
82. van de Rest O, Geleijnse JM, Kok FJ, et al. Effect of fish-oil supplementation on mental well-being in older subjects: a randomized double-blind, placebo-controlled trial. Am J Clin Nutr 2008; 88: 706-13.
83. Buydens-Branchey L, Branchey M, Hibbeln JR. Associations between increases in plasma n-3 polyunsaturated fatty acids following supplementation and decreases in anger and anxiety. Prog Neuropsychopharmacol Biol Psychiaty 2008; 32: 568-75.
84. Lucas M, Asselin G, Merette C, Poulin MJ, Dodin S. Ethyleicosapentaenoic acid for treatment of psychological distress and depressive symptoms in middle-aged women: a double-blind, placebo-controlled, randomized clinical trial. Am J Clin Nutr 2009; 89: 641-51.
85. Issa AM, Mojica WA, Morton SC, et al. The Efficacy of Omega-3 Fatty Acids on Cognitive Function in Aging and Dementia: A Systematic Review. Dement Geriatr Cogn Disord 2006; 21: 88-96.
86. Morris MC, Evans DA, Tangney CC, Bienias JL, Wilson RS. Fish consumption and cognitive decline with age in a large community study. Arch Neurol 2005; 62(12): 1849-53.
87. Heude B, Ducimetiere P, Berr C. Cognitive decline and fatty acid composition of erythrocyte membranes - The EVA Study. Am J Clin Nutr 2003; 77: 803-8
88. Kalmijn S, Launer LJ, Ott A, Witteman JC, Hofman A, Breteler MM. Dietary fat intake and the risk of incident dementia in the Rotterdam study. Ann Neurol 1997; 42: 776-82.
89. Moriguchi T, Salem N. Rocovery of branin docosahexaenoate leads to recovery spatial performance. J Neurochem 2003; 87: 297-309.
90. Whalley LJ, Fox HC, Waje KW, Starr JM, Deary IJ. Cognitive aging, childhood intelligence, and the use of food supplements: possible involvement of n-3 fatty acids. Am J Clin Nutr 2004; 80: 1650-7.
91. Whalley LJ, Deary IJ, Starr JM, et al. N-3 fatty acid erythrocyte membrane content, APOE 4, and cognitive variation: an observational follow-up study in late adulthood. Am J Clin Nutr 2008; 87: 449-54.
92. Nurk E, Drevon CA, Refsum H, et al. Cognitive performance among the elderly and dietary fish intake: the Hordaland Health Study. Am J Clin Nutr 2007; 86: 1470-8.
93. Dullemeijer C, Durga J, Brouwer IA, et al. n-3 fatty acid proportions in plasma and cognitive performance in older adults. Am J Clin Nutr 2007; 86: 1479-85.
94. Sawada T, Yokoi K. Effect of zinc supplementation on mood states in young women: a pilot study. Eur J Clin Nutr 2010; 64(3): 331-3.
95. Cornelissen G, Watson D, Mitsutake G, et al. Mapping of circaseptan andcircadian changes in mood. Scr Med 2005; 78: 89-98.
96. Halberg F. Physiologic considerations underlying rhythmometry, withspecial reference to emotional illness. Symposium on Biological Cycles and Psychiatry. In: Ajuriaguerra J de, Ed. Symposium Bel-Air III. Cyclesbiologiques et psychiatrie. Geneva: Georg/Paris: Masson et Cie; 1968. pp. 73-126.